ReviewMaterials today. Bio2025
Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular pathological neovascularization is a significant pathological alteration associated with various ocular diseases, which could lead to substantial vision loss. Currently, anti-vascular endothelial growth factor (VEGF) agent is one of the primary therapeutic strategies of anti-angiogenesis. However, this approach is often accompanied by severe complications and side effects, underscoring the urgent need for novel therapeutic strategies. In recent years, due to the excellent physical and chemical properties of inorganic nanomaterials, they could be functionally modified to achieve anti-angiogenesis function, or integrated with other nanmaterials (such as exosomes, liposomes), so as to help achieve intraocular targeted therapy and enhance the therapeutic effect of ocular neovascularization, and have been widely developed and explored in anti-angiogenesis therapy. This review summarizes the latest advancements in the application of inorganic nanomaterials for the treatment of ocular neovascularization. The pathological features of ocular neovascularization, along with current treatment strategies and their limitations, are discussed. The characteristics and advantages of inorganic nanomaterials, including both metal and non-metal types, are summarized. In addition, the specific applications of these materials for the ocular neovascularization treatment are comprehensively reviewed. Based on the current advances, this review also looks forward to provide valuable insights into the development of inorganic nanomaterials for anti-angiogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.